Pharmocogenomics has not fulfilled its promise to developing countries

April 2, 2014, University of Montreal

From 1997 to 2010, despite promises made by the international scientific community, pharmacogenomic research produced few studies focusing on rare, orphan and tropical diseases prevalent in developing countries. Catherine Olivier, bioethics research at the University of Montreal's School of Public Health, recently published these findings in the journal Global Public Health.

Pharmcogenomics is a field of that studies the interaction between the genomic information of individuals (or populations) and their responses to drugs. In addition to its promising potential for the emergence of , held the potential to contribute to the development and accessibility of treatments for rare and orphan diseases – including tropical infections – in developing countries.

In general, "it is recognized that the distribution of technology and research follows the so-called 90/10 ratio rule, that is, 90% of global funding for health research, including the development drugs, is invested to treat 10% of the world's population," Olivier explained. This inequality between rich and poor countries had led the United Nations (UN) to make the fight against HIV-AIDS, malaria, and neglected one of its eight Millennium Development Goals, adopted in September 2000 by the 189 UN member states.

More than 600 studies analyzed

To verify the extent to which pharmacogenomics research has addressed rare, orphan, and tropical diseases, Olivier identified the focus of studies published in this area from 1997 to 2010.

As a result, she identified 626 studies published in 171 different journals.

Each study was analyzed according to the type of disease it concerned, the origin of its authors, and the latter's affiliation with pharmaceutical companies, if any. "The information collected allowed us to draw a map showing current and historical trends in the development of pharmacogenomic research," Olivier said.

Few studies on rare diseases

Consequently, she found that from 1997 to 2003, there were 401 publications on pharmacogenomics identified in the PubMed database – the majority (67%) being published in a single journal, Pharmacogenetics. Then, from 2003 to 2010, the number of studies published doubled.

However, the apparent enthusiasm for this type of research seems to have been artificially inflated. Olivier noted that the percentage of non-original publications, including reviews, meta-analyses, and debates, increased from 15% in 1997 to 51% in 2010. "The number of original articles, that is, studies focusing on a new aspect of pharmacogenomics, began to decline after 2002," Olivier said. Moreover, during the period analyzed, nearly 23% of published studies in pharmacogenomics dealt with the area of oncology, followed by depression and psychological disorders (14.7%), and cardiovascular disorders (13.6%).

"Rare diseases, tropical infections, and maternal health, which should have benefited from pharmacogenomic research under the Millennium Development Goals, represented only 3.8% of published studies," Olivier explained.

Researchers uninterested

According to Olivier, it is also troubling that researchers from countries most likely to be interested in this area nevertheless conducted few studies on rare diseases and tropical infections. "Of the 65 publications from BRICS countries – Brazil, Russia, India, China, and South Africa – only two concerned rare diseases and tropical infections," Olivier said.

Yet, these diseases represented nearly half (45.5%) of the main causes of mortality in underdeveloped countries, and 15% in developing , according to 2008 data issued by the UN. "Unfortunately, our study indicates that we are far from fulfilling the promise to reduce health inequalities in the world, a promise which was made before the adoption of the Millennium Declaration," Olivier said.

Explore further: Drugs improvement to combat Trypanosomatidic infections

Related Stories

Drugs improvement to combat Trypanosomatidic infections

March 19, 2014
If you live in Europe, you may never have heard of 'neglected diseases' from Trypanosomatidic infections. However, in countries like Brazil or Sudan these diseases are endemic.

More research into chronic diseases urgently needed in all countries

January 29, 2013
When considering chronic (non-communicable) diseases, such as cardiovascular disease and diabetes, in low-and-middle countries, a major shift in approach from declaring what needs to be done to using research to prioritise, ...

Non-specialist health workers play important role in improving mental health in developing countries

November 19, 2013
Non-specialist health workers are beneficial in providing treatment for people with mental, neurological and substance-abuse (MNS) problems in developing countries – where there is often a lack of mental health professionals ...

EU releases 144 mn euro for new rare disease research

February 28, 2013
The European Union on Thursday pledged 144 million euros of fresh funding for research on rare diseases that currently affect some 30 million Europeans, the majority of them children.

UK funding for infectious disease research neglects key areas of disease

November 8, 2012
The research undertaken by researchers at University College, Imperial College, and the London School of Hygiene and Tropical Medicine is the first ever detailed assessment of infectious diseases investments made by funding ...

Recommended for you

Women run faster after taking newly developed supplement, study finds

January 19, 2018
A new study found that women who took a specially prepared blend of minerals and nutrients for a month saw their 3-mile run times drop by almost a minute.

Americans are getting more sleep

January 19, 2018
Although more than one in three Americans still don't get enough sleep, a new analysis shows first signs of success in the fight for more shut eye. According to data from 181,335 respondents aged 15 and older who participated ...

Wine is good for you—to a point

January 18, 2018
The Mediterranean diet has become synonymous with healthy eating, but there's one thing in it that stands out: It's cool to drink wine.

Sleep better, lose weight?

January 17, 2018
(HealthDay)—Sleeplessness could cost you when it's time to stand on your bathroom scale, a new British study suggests.

Who uses phone apps to track sleep habits? Mostly the healthy and wealthy in US

January 16, 2018
The profile of most Americans who use popular mobile phone apps that track sleep habits is that they are relatively affluent, claim to eat well, and say they are in good health, even if some of them tend to smoke.

Improvements in mortality rates are slowed by rise in obesity in the United States

January 15, 2018
With countless medical advances and efforts to curb smoking, one might expect that life expectancy in the United States would improve. Yet according to recent studies, there's been a reduction in the rate of improvement in ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.